Table 1 Patient demographics, baseline and study characteristics
From: Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
Study, year, trial registration, and reference | Study characteristics | Study duration (weeks) | Enrolled patients | Treatments and doses | Concomitant medications for asthma | Disease characteristics | Age (years) | Male (%) | Asthma events (n/day) | Previous hospitalization for asthma (%) | FEV1 (% predicted) | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calzetta et al., 2018, DOROTHEO 1, ISRCTN65297911, http://www.isrctn.com/ISRCTN65297911, [8] | Multicentre, double-blind, randomized, placebo-controlled, parallel-group | 12 | 346 | Doxofylline 200 mg t.i.d., doxofylline 400 mg t.i.d., theophylline 250 mg t.i.d., placebo | Salbutamol as needed | FEV1 ≥ 50 and < 80%, ≥15% post-bronchodilator increase in FEV1 | 36 | 49 | 1.2 | 40 | 66 | 5 |
Calzetta et al., 2018, DOROTHEO 2, ISRCTN65297911, http://www.isrctn.com/ISRCTN22374987, [8] | Multicentre, double-blind, randomized, placebo-controlled, parallel-group | 12 | 220 | Doxofylline 400 mg t.i.d., theophylline 250 mg t.i.d., placebo | Salbutamol as needed | FEV1 ≥ 50 and < 80%, ≥15% post-bronchodilator increase in FEV1 | 37 | 45 | 1.0 | 42 | 67 | 5 |
Lal et al., 2015, NA, [10] | Single-centre, open, parallel-group | 8 | 30 | Doxofylline 200 mg b.i.d., theophylline 200 mg b.i.d. | Standard treatment | NA | 35 | NA | NA | NA | NA | 1 |
Margay et al., 2015, NA, [9] | Single-centre, open, randomized, parallel-group | 6 | 100 | Doxofylline 400 mg b.i.d., theophylline 300 mg b.i.d. | Salbutamol as needed | FEV1 ≥ 50% and ≤ 80%, ≥12% post-bronchodilator increase in FEV1 | 38 | 45 | 1.7 | NA | 68 | 3 |